Floatz logo

13C-Fructose

HLRCC

University of Texas Southwestern Medical CenterN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the HLRCC cohort.

Asset / SponsorPhaseRating
Atezolizumab
National Cancer Institute (NCI)
Phase 2CCC
DENTALFLUORO
National Cancer Institute (NCI)
Phase 2CCC
Pamiparib
Jonsson Comprehensive Cancer Center
Phase 2CCC
Metformin
National Cancer Institute (NCI)
Phase 1/2CCC
Zactima
National Cancer Institute (NCI)
Phase 1/2CCC

View all 9 →

Same molecule, other indications

13C-Fructose is also rated in:

kidney cancerDormant
D
Indicative ·
30 / 100
View asset →
clear cell adenocarcinomaDormant
D
Indicative ·
30 / 100
View asset →
urothelial carcinomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →